Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ACCELERON PHARMA INCXLRN · Entity 15780 | EVP, Chief Business Officer | January 02, 2020 | January 03, 2020 |
| Disc Medicine, Inc.IRON · Entity 2273 | Director · Chief Executive Officer | September 15, 2026 | September 16, 2026 |
| Gossamer Bio, Inc.GOSS · Entity 6928 | Director | September 23, 2026 | September 25, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ACCELERON PHARMA INC
Report date January 02, 2020 · Filed January 03, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 53,316 |
Ending reported balance
After 2020-01-02 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2020-01-02 · Sale · Disposed 1,600 · Balance 57,558 F1: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.12 to $52.83 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Row 2 · 2020-01-02 · Sale · Disposed 4,242 · Balance 53,316 F1: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.12 to $52.84 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.12 to $52.83 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.12 to $52.84 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.
Disc Medicine, Inc.
Report date September 15, 2026 · Filed September 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 262,064 |
Reported balance
After 2026-09-15 transaction · row 1
1 source rowRow 1 · 2026-09-15 · Exercise / conversion · Acquired 36,000 · Balance 262,064 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.01 · Expires 2030-03-10 | Direct | 150,120 |
Reported balance
After 2026-09-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-09-15 · Exercise / conversion · Disposed 36,000 · Balance 150,120 F1: The shares underlying this option are fully vested and exercisable as of the date hereof. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option are fully vested and exercisable as of the date hereof.
Gossamer Bio, Inc.
Report date September 23, 2026 · Filed September 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.99 · Expires 2036-09-22 | Direct | 10,000 |
Reported balance
After 2026-09-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-23 · Grant · Acquired 10,000 · Balance 10,000 F1: The entire number of shares subject to this option becomes fully vested and exercisable on the first anniversary of the grant date, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The entire number of shares subject to this option becomes fully vested and exercisable on the first anniversary of the grant date, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 30, 2024 Filed Jan 3, 2025 00:13 UTC | Disc Medicine, Inc. IRON · Entity 2273 | SaleCommon Stock | 1,900 | $62.41 | $118,580.33 |
DisclosureSEC source: 0000950170-25-000617 · ownership.xml · nonDerivative · entry 3 Quisel John D · CIK 0001586788 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 72,065 F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on July 2, 2024. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.31 to $62.58, inclusive. Read SEC document |
| December 30, 2024 Filed Jan 3, 2025 00:13 UTC | Disc Medicine, Inc. IRON · Entity 2273 | SaleCommon Stock | 11,112 | $61.87 | $687,477.22 |
DisclosureSEC source: 0000950170-25-000617 · ownership.xml · nonDerivative · entry 2 Quisel John D · CIK 0001586788 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 73,965 F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on July 2, 2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.29 to $62.27, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4. Read SEC document |
| December 30, 2024 Filed Jan 3, 2025 00:13 UTC | Disc Medicine, Inc. IRON · Entity 2273 | Exercise / conversionCommon Stock | 13,012 | $9.86 | $128,298.32 |
DisclosureSEC source: 0000950170-25-000617 · ownership.xml · nonDerivative · entry 1 Quisel John D · CIK 0001586788 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 85,077 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on July 2, 2024. Read SEC document |
| December 23, 2024 Filed Dec 26, 2024 22:18 UTC | Disc Medicine, Inc. IRON · Entity 2273 | Exercise / conversionStock Option (Right to Buy) · Derivative | 19,820 | $0.00 Strike: $2.65 | $0.00 |
DisclosureSEC source: 0000950170-24-140502 · ownership.xml · derivative · entry 5 Quisel John D · CIK 0001586788 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 41,830 Underlying: Common Stock · 19,820 shares Expires 2030-10-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on July 2, 2024. F5 · derivative.exercise_date: The shares underlying this option are fully vested and exercisable as of the date hereof. Read SEC document |
| December 23, 2024 Filed Dec 26, 2024 22:18 UTC | Disc Medicine, Inc. IRON · Entity 2273 | SaleCommon Stock | 4,212 | $63.80 | $268,732.76 |
DisclosureSEC source: 0000950170-24-140502 · ownership.xml · nonDerivative · entry 4 Quisel John D · CIK 0001586788 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 72,065 F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on July 2, 2024. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.695 to $63.86, inclusive. Read SEC document |
| December 23, 2024 Filed Dec 26, 2024 22:18 UTC | Disc Medicine, Inc. IRON · Entity 2273 | SaleCommon Stock | 12,194 | $63.12 | $769,666.99 |
DisclosureSEC source: 0000950170-24-140502 · ownership.xml · nonDerivative · entry 3 Quisel John D · CIK 0001586788 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 76,277 F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on July 2, 2024. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.66 to $63.655, inclusive. Read SEC document |
| December 23, 2024 Filed Dec 26, 2024 22:18 UTC | Disc Medicine, Inc. IRON · Entity 2273 | SaleCommon Stock | 3,414 | $62.38 | $212,957.47 |
DisclosureSEC source: 0000950170-24-140502 · ownership.xml · nonDerivative · entry 2 Quisel John D · CIK 0001586788 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 88,471 F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on July 2, 2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.66 to $62.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this Form 4. Read SEC document |
| December 23, 2024 Filed Dec 26, 2024 22:18 UTC | Disc Medicine, Inc. IRON · Entity 2273 | Exercise / conversionCommon Stock | 19,820 | $2.65 | $52,523.00 |
DisclosureSEC source: 0000950170-24-140502 · ownership.xml · nonDerivative · entry 1 Quisel John D · CIK 0001586788 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 91,885 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on July 2, 2024. Read SEC document |
| December 16, 2024 Filed Dec 19, 2024 00:41 UTC | Disc Medicine, Inc. IRON · Entity 2273 | Exercise / conversionStock Option (Right to Buy) · Derivative | 12,791 | $0.00 Strike: $1.01 | $0.00 |
DisclosureSEC source: 0000950170-24-138086 · ownership.xml · derivative · entry 6 Quisel John D · CIK 0001586788 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 225,420 Underlying: Common Stock · 12,791 shares Expires 2030-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on July 2, 2024. F6 · derivative.exercise_date: The shares underlying this option are fully vested and exercisable as of the date hereof. Read SEC document |
| December 16, 2024 Filed Dec 19, 2024 00:41 UTC | Disc Medicine, Inc. IRON · Entity 2273 | SaleCommon Stock | 500 | $67.20 | $33,599.00 |
DisclosureSEC source: 0000950170-24-138086 · ownership.xml · nonDerivative · entry 5 Quisel John D · CIK 0001586788 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 72,065 F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on July 2, 2024. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.04 to $67.54, inclusive. Read SEC document |
| December 16, 2024 Filed Dec 19, 2024 00:41 UTC | Disc Medicine, Inc. IRON · Entity 2273 | SaleCommon Stock | 6,305 | $66.35 | $418,361.34 |
DisclosureSEC source: 0000950170-24-138086 · ownership.xml · nonDerivative · entry 4 Quisel John D · CIK 0001586788 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 72,565 F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on July 2, 2024. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.04 to $67.01, inclusive. Read SEC document |
| December 16, 2024 Filed Dec 19, 2024 00:41 UTC | Disc Medicine, Inc. IRON · Entity 2273 | SaleCommon Stock | 5,767 | $65.58 | $378,193.52 |
DisclosureSEC source: 0000950170-24-138086 · ownership.xml · nonDerivative · entry 3 Quisel John D · CIK 0001586788 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 78,870 F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on July 2, 2024. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.04 to $66.03, inclusive. Read SEC document |
| December 16, 2024 Filed Dec 19, 2024 00:41 UTC | Disc Medicine, Inc. IRON · Entity 2273 | SaleCommon Stock | 219 | $64.66 | $14,160.23 |
DisclosureSEC source: 0000950170-24-138086 · ownership.xml · nonDerivative · entry 2 Quisel John D · CIK 0001586788 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 84,637 F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on July 2, 2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.04 to $65.02, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4) and (5) to this Form 4. Read SEC document |
| December 16, 2024 Filed Dec 19, 2024 00:41 UTC | Disc Medicine, Inc. IRON · Entity 2273 | Exercise / conversionCommon Stock | 12,791 | $1.01 | $12,918.91 |
DisclosureSEC source: 0000950170-24-138086 · ownership.xml · nonDerivative · entry 1 Quisel John D · CIK 0001586788 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 84,856 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on July 2, 2024. Read SEC document |
| July 08, 2024 Filed Jul 10, 2024 20:15 UTC | Disc Medicine, Inc. IRON · Entity 2273 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $1.01 | $0.00 |
DisclosureSEC source: 0000950170-24-082693 · ownership.xml · derivative · entry 2 Quisel John D · CIK 0001586788 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 238,211 Underlying: Common Stock · 3,000 shares Expires 2030-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares underlying this option are fully vested and exercisable as of the date hereof. Read SEC document |
| July 08, 2024 Filed Jul 10, 2024 20:15 UTC | Disc Medicine, Inc. IRON · Entity 2273 | Exercise / conversionCommon Stock | 3,000 | $1.01 | $3,030.00 |
DisclosureSEC source: 0000950170-24-082693 · ownership.xml · nonDerivative · entry 1 Quisel John D · CIK 0001586788 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,065 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 06, 2024 Filed Jun 7, 2024 01:59 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | GrantNon-qualified stock option (Right to Buy) · Derivative | 115,000 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001728117-24-000067 · wk-form4_1717725537.xml · derivative · entry 1 Quisel John D · CIK 0001586788 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 115,000 Underlying: Common Stock · 115,000 shares Expires 2034-06-05 F1 · shares: Award made pursuant to Non-Employee Director Compensation Program. F2 · derivative.exercise_date: The entire number of shares subject to this option becomes fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. Read SEC document |
| January 10, 2024 Filed Mar 2, 2024 00:42 UTC | Disc Medicine, Inc. IRON · Entity 2273 | GrantStock Option (Right to Buy) · Derivative | 99,550 | $0.00 Strike: $63.90 | $0.00 |
DisclosureSEC source: 0000950170-24-024199 · ownership.xml · derivative · entry 2 Quisel John D · CIK 0001586788 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 99,550 Underlying: Common Stock · 99,550 shares Expires 2034-01-09 F1 · derivative.exercise_date: 25% of the shares underlying this option shall vest and become exercisable on January 10, 2025, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| January 10, 2024 Filed Mar 2, 2024 00:42 UTC | Disc Medicine, Inc. IRON · Entity 2273 | GrantCommon Stock | 66,365 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-024199 · ownership.xml · nonDerivative · entry 1 Quisel John D · CIK 0001586788 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,065 Read SEC document |
| December 29, 2023 Filed Jan 3, 2024 21:05 UTC | Disc Medicine, Inc. IRON · Entity 2273 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,700 | $0.00 Strike: $1.01 | $0.00 |
DisclosureSEC source: 0000950170-24-000880 · ownership.xml · derivative · entry 2 Quisel John D · CIK 0001586788 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 241,211 Underlying: Common Stock · 2,700 shares Expires 2030-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 25% of the shares underlying this option vested on February 25, 2021, with the remaining shares vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| December 29, 2023 Filed Jan 3, 2024 21:05 UTC | Disc Medicine, Inc. IRON · Entity 2273 | Exercise / conversionCommon Stock | 2,700 | $1.01 | $2,727.00 |
DisclosureSEC source: 0000950170-24-000880 · ownership.xml · nonDerivative · entry 1 Quisel John D · CIK 0001586788 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,700 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 28, 2023 Filed Nov 29, 2023 23:38 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | GrantStock Option (Right to Buy) · Derivative | 230,000 | $0.00 Strike: $0.69 | $0.00 |
DisclosureSEC source: 0001728117-23-000160 · wk-form4_1701301079.xml · derivative · entry 1 Quisel John D · CIK 0001586788 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 230,000 Underlying: Common Stock · 230,000 shares Expires 2033-11-27 F1 · derivative.exercise_date: 1/36th of the total number of shares subject to the option vest on the last day of each one-month period thereafter, subject to the Reporting Person's continuous service to the Corporation on each such vesting date. Read SEC document |
| December 29, 2022 Filed Jan 3, 2023 22:05 UTC | Disc Medicine, Inc. IRON · Entity 2273 | GrantStock Option (Right to Buy) · Derivative | 132,002 | $0.00 Strike: $13.50 | $0.00 |
DisclosureSEC source: 0000899243-23-000297 · doc4.xml · derivative · entry 1 Quisel John D · CIK 0001586788 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,002 Underlying: Common Stock · 132,002 shares Expires 2032-12-28 F1 · derivative.exercise_date: The shares underlying this option vest in 48 equal monthly installments following December 29, 2022, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| January 02, 2020 Filed Jan 3, 2020 21:45 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | SaleCommon Stock | 4,242 | $52.52 | $222,789.84 |
DisclosureSEC source: 0001179110-20-000274 · edgar.xml · nonDerivative · entry 2 Quisel John D · CIK 0001586788 · EVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,316 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.12 to $52.84 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4. Read SEC document |
| January 02, 2020 Filed Jan 3, 2020 21:45 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | SaleCommon Stock | 1,600 | $52.51 | $84,016.00 |
DisclosureSEC source: 0001179110-20-000274 · edgar.xml · nonDerivative · entry 1 Quisel John D · CIK 0001586788 · EVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,558 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.12 to $52.83 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| September 10, 2019 Filed Sep 10, 2019 20:23 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | SaleCommon Stock | 3,584 | $45.23 | $162,104.32 |
DisclosureSEC source: 0001179110-19-010221 · edgar.xml · nonDerivative · entry 1 Quisel John D · CIK 0001586788 · EVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,158 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.86 to $45.65 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| July 09, 2019 Filed Jul 11, 2019 16:26 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | Exercise / conversionOption to Purchase Common Stock · Derivative | 1,562 | $0.00 Strike: $7.12 | $0.00 |
DisclosureSEC source: 0001179110-19-008579 · edgar.xml · derivative · entry 6 Quisel John D · CIK 0001586788 · EVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,562 shares Expires 2022-12-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares of common stock underlying this option award vested in equal quarterly installments over the first four years after the grant. Read SEC document |
| July 09, 2019 Filed Jul 11, 2019 16:26 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | Exercise / conversionOption to Purchase Common Stock · Derivative | 2,346 | $0.00 Strike: $5.28 | $0.00 |
DisclosureSEC source: 0001179110-19-008579 · edgar.xml · derivative · entry 5 Quisel John D · CIK 0001586788 · EVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,346 shares Expires 2021-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares of common stock underlying this option award vested in equal quarterly installments over the first four years after the grant. Read SEC document |
| July 09, 2019 Filed Jul 11, 2019 16:26 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | Exercise / conversionOption to Purchase Common Stock · Derivative | 5,000 | $0.00 Strike: $3.88 | $0.00 |
DisclosureSEC source: 0001179110-19-008579 · edgar.xml · derivative · entry 4 Quisel John D · CIK 0001586788 · EVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2020-12-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares of common stock underlying this option award vested in equal quarterly installments over the first four years after the grant. Read SEC document |
| July 09, 2019 Filed Jul 11, 2019 16:26 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | Exercise / conversionCommon Stock | 1,562 | $7.12 | $11,121.44 |
DisclosureSEC source: 0001179110-19-008579 · edgar.xml · nonDerivative · entry 3 Quisel John D · CIK 0001586788 · EVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,742 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 09, 2019 Filed Jul 11, 2019 16:26 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | Exercise / conversionCommon Stock | 2,346 | $5.28 | $12,386.88 |
DisclosureSEC source: 0001179110-19-008579 · edgar.xml · nonDerivative · entry 2 Quisel John D · CIK 0001586788 · EVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,180 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 09, 2019 Filed Jul 11, 2019 16:26 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | Exercise / conversionCommon Stock | 5,000 | $3.88 | $19,400.00 |
DisclosureSEC source: 0001179110-19-008579 · edgar.xml · nonDerivative · entry 1 Quisel John D · CIK 0001586788 · EVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,834 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 09, 2019 Filed Apr 11, 2019 16:58 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | SaleCommon Stock | 70 | $44.24 | $3,096.80 |
DisclosureSEC source: 0001179110-19-004912 · edgar.xml · nonDerivative · entry 3 Quisel John D · CIK 0001586788 · EVP, CBO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,834 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| April 09, 2019 Filed Apr 11, 2019 16:58 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | SaleCommon Stock | 100 | $45.46 | $4,546.00 |
DisclosureSEC source: 0001179110-19-004912 · edgar.xml · nonDerivative · entry 2 Quisel John D · CIK 0001586788 · EVP, CBO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,904 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| April 09, 2019 Filed Apr 11, 2019 16:58 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | SaleCommon Stock | 3,452 | $44.62 | $154,028.24 |
DisclosureSEC source: 0001179110-19-004912 · edgar.xml · nonDerivative · entry 1 Quisel John D · CIK 0001586788 · EVP, CBO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,004 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.31 to $45.05 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| January 25, 2019 Filed Jan 29, 2019 17:41 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | GrantOption to Purchase Common Stock · Derivative | 28,500 | $0.00 Strike: $41.64 | $0.00 |
DisclosureSEC source: 0001179110-19-001055 · edgar.xml · derivative · entry 2 Quisel John D · CIK 0001586788 · EVP, CBO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,500 Underlying: Common Stock · 28,500 shares Expires 2029-01-25 F1 · derivative.exercise_date: The shares of common stock underlying this stock option award vest in equal quarterly installments over the four years after January 1, 2019. Read SEC document |
| January 25, 2019 Filed Jan 29, 2019 17:41 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | GrantCommon Stock | 4,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-001055 · edgar.xml · nonDerivative · entry 1 Quisel John D · CIK 0001586788 · EVP, CBO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,456 Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 18:35 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | SaleCommon Stock | 475 | $43.92 | $20,862.00 |
DisclosureSEC source: 0001179110-19-000469 · edgar.xml · nonDerivative · entry 5 Quisel John D · CIK 0001586788 · EVP, CBO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,656 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.87 to $44.08 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (6) to this Form 4. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 18:35 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | SaleCommon Stock | 2,558 | $43.10 | $110,249.80 |
DisclosureSEC source: 0001179110-19-000469 · edgar.xml · nonDerivative · entry 4 Quisel John D · CIK 0001586788 · EVP, CBO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,131 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.78 to $43.66 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (5) to this Form 4. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 18:35 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | SaleCommon Stock | 1,300 | $42.31 | $55,003.00 |
DisclosureSEC source: 0001179110-19-000469 · edgar.xml · nonDerivative · entry 3 Quisel John D · CIK 0001586788 · EVP, CBO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,689 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.78 to $42.74 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4) to this Form 4. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 18:35 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | SaleCommon Stock | 300 | $43.26 | $12,978.00 |
DisclosureSEC source: 0001179110-19-000469 · edgar.xml · nonDerivative · entry 2 Quisel John D · CIK 0001586788 · EVP, CBO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,989 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.15 to $43.47 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 18:35 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | SaleCommon Stock | 1,309 | $42.32 | $55,396.88 |
DisclosureSEC source: 0001179110-19-000469 · edgar.xml · nonDerivative · entry 1 Quisel John D · CIK 0001586788 · EVP, CBO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,289 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.77 to $42.76 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| May 10, 2018 Filed May 11, 2018 16:59 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | GrantOption to Purchase Common Stock · Derivative | 10,000 | $0.00 Strike: $34.94 | $0.00 |
DisclosureSEC source: 0001179110-18-006662 · edgar.xml · derivative · entry 2 Quisel John D · CIK 0001586788 · EVP, CBO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2028-05-10 F1 · derivative.exercise_date: The options of registrant's common stock vest in equal quarterly installments over the first four years after the grant. Read SEC document |
| May 10, 2018 Filed May 11, 2018 16:59 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | GrantCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-006662 · edgar.xml · nonDerivative · entry 1 Quisel John D · CIK 0001586788 · EVP, CBO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,598 Read SEC document |
| April 03, 2018 Filed Apr 4, 2018 16:40 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | SaleCommon Stock | 100 | $39.16 | $3,916.00 |
DisclosureSEC source: 0001179110-18-005398 · edgar.xml · nonDerivative · entry 2 Quisel John D · CIK 0001586788 · SVP, Corp. Dev., GC & Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,598 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| April 03, 2018 Filed Apr 4, 2018 16:40 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | SaleCommon Stock | 1,104 | $38.33 | $42,316.32 |
DisclosureSEC source: 0001179110-18-005398 · edgar.xml · nonDerivative · entry 1 Quisel John D · CIK 0001586788 · SVP, Corp. Dev., GC & Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,698 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.90 to $38.89 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 17:14 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | GrantOption to Purchase Common Stock · Derivative | 28,950 | $0.00 Strike: $40.61 | $0.00 |
DisclosureSEC source: 0001179110-18-003495 · edgar.xml · derivative · entry 2 Quisel John D · CIK 0001586788 · SVP, Corp. Dev., GC & Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,950 Underlying: Common Stock · 28,950 shares Expires 2028-03-01 F1 · derivative.exercise_date: The shares of common stock underlying this stock option award vest in equal quarterly installments over the four years after January 1, 2018. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 17:14 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | GrantCommon Stock | 4,825 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-003495 · edgar.xml · nonDerivative · entry 1 Quisel John D · CIK 0001586788 · SVP, Corp. Dev., GC & Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,802 Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 19:03 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | SaleCommon Stock | 4,333 | $42.42 | $183,805.86 |
DisclosureSEC source: 0001179110-18-000547 · edgar.xml · nonDerivative · entry 1 Quisel John D · CIK 0001586788 · SVP, Corp. Dev., GC & Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,977 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.95 to $42.88 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| September 13, 2017 Filed Sep 14, 2017 17:03 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | SaleCommon Stock | 8 | $38.03 | $304.24 |
DisclosureSEC source: 0001179110-17-012289 · edgar.xml · nonDerivative · entry 3 Quisel John D · CIK 0001586788 · SVP, Corp. Dev., GC & Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,310 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.